TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16427165

Group type: EXPERIMENTAL
Intervention: Unstable ankles during v-cut movement
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls during v-cut movement
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Unstable ankles during lateral shuffling
Number of subjects: 32

Group type: COMPARATOR
Intervention: Controls during lateral shuffling
Number of subjects: 32
Study: 12611746

Group type: EXPERIMENTAL
Intervention: Donepezil (10 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 10883416

Group type: EXPERIMENTAL
Intervention: AMP 579 (50 micrograms/kg as a 6-hour constant-rate intravenous infusion)
Number of subjects: 0
Study: 9332892

Group type: EXPERIMENTAL
Intervention: Ribomunyl
Number of subjects: 327

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study: 8457937

Group type: EXPERIMENTAL
Intervention: Computer Assisted Instruction (CAI)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Small-group review
Number of subjects: 123
Study: 3782621

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of methylphenidate and cognitive therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no medication during post‐testing)
Number of subjects: 0
Study: 30840639

Group type: EXPERIMENTAL
Intervention: Cigarettes described as "organic"
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Cigarettes described as "natural"
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: Cigarettes described as "additive-free"
Number of subjects: 1101

Group type: COMPARATOR
Intervention: Cigarettes described as "ultra-light"
Number of subjects: 1101

Group type: EXPERIMENTAL
Intervention: All four types of cigarettes ("organic," "natural," "additive-free," and "ultra-light")
Number of subjects: 1101
Study: 29298257

Group type: EXPERIMENTAL
Intervention: Health behavior change counseling
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 122
Study: 27033686

Group type: EXPERIMENTAL
Intervention: Attention-to-breath (ATB) meditation
Number of subjects: 26
Study: 24947950

Group type: EXPERIMENTAL
Intervention: 500 mg I/V metronidazole and 1 g Ceftriaxone I/V before induction of anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: No prophylactic antibiotics
Number of subjects: 100
Study: 22118795

Group type: EXPERIMENTAL
Intervention: Vascular imaging performed in 61 patients
Number of subjects: 113
Study: 19087155

Group type: EXPERIMENTAL
Intervention: Subcutaneous histamine (1-10 ng twice a week)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Botulinum toxin type A (50 U, one injection cycle)
Number of subjects: 100
Study: 17355457

Group type: EXPERIMENTAL
Intervention: RFA combined with arterial occlusion (group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: RFA alone (group B)
Number of subjects: 20
Study: 12548308

Group type: EXPERIMENTAL
Intervention: PABA15 (80 mg at 08:00, 12:00, and 15:00)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: PABA18 (80 mg at 08:00, 12:00, and 18:00)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Single dosage of 80 mg PABA
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: 240 mg PABA at recommended hours
Number of subjects: 99

Group type: COMPARATOR
Intervention: Recommended dosage schedule (PABA taken with main meals)
Number of subjects: 99
Study: 10700656

Group type: EXPERIMENTAL
Intervention: Amitriptyline treatment for 6 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control subjects (not specified how many)
Number of subjects: 24
Study: 9568324

Group type: EXPERIMENTAL
Intervention: Trypsin: chymotrypsin preparation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 0
Study: 8446846

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 229

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 229
Study: 3017804

Group type: EXPERIMENTAL
Intervention: 5-aminosalicylic acid (1 g daily enema)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prednisolone (25 mg daily enema)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 24
Study: 31898198

Group type: EXPERIMENTAL
Intervention: Walking group
Number of subjects: 40

Group type: COMPARATOR
Intervention: Sitting group
Number of subjects: 40
Study: 30097359

Group type: EXPERIMENTAL
Intervention: 150 mg risankizumab
Number of subjects: 997

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 997

Group type: COMPARATOR
Intervention: 45 mg or 90 mg ustekinumab
Number of subjects: 997
Study: 27637589

Group type: EXPERIMENTAL
Intervention: Single prolonged maximum voluntary contractions (MVCs)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated short maximum voluntary contractions (MVCs)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Single all-out cycling bouts
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated all-out cycling bouts
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Repeated drop jumps
Number of subjects: 9
Study: 24687506

Group type: EXPERIMENTAL
Intervention: Liposomal amikacin for inhalation (LAI) 560 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21962978

Group type: EXPERIMENTAL
Intervention: Active tDCS (1 or 2 mA for 20 minutes/day for 2 weeks)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tDCS (sham stimulation for 2 weeks)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo tDCS
Number of subjects: 22
Study: 21144224

Group type: EXPERIMENTAL
Intervention: Steroid-infused carboxymethylcellulose (CMC) foam, 4 mL hydrated with triamcinolone, 40 mg/mL (Kenalog 40)
Number of subjects: 8
Study: 18506677

Group type: EXPERIMENTAL
Intervention: Violent computer game (Unreal Tournament) with VR device
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Violent computer game (Unreal Tournament) without VR device
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-violent game (Motocross Madness) with VR device
Number of subjects: 148

Group type: COMPARATOR
Intervention: Non-violent game (Motocross Madness) without VR device
Number of subjects: 148
Study: 16430197

Group type: EXPERIMENTAL
Intervention: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at baseline (Group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Switching from protease inhibitors to efavirenz and from stavudine to tenofovir at week 24 (Group 2)
Number of subjects: 28
Study: 12856476

Group type: EXPERIMENTAL
Intervention: Patients with left hemispheric lesion
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Patients with right hemisphere lesion
Number of subjects: 17

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 17
Study: 11783238

Group type: EXPERIMENTAL
Intervention: Sijunzi Decoction (SJZD)
Number of subjects: 66
Study: 9046507

Group type: EXPERIMENTAL
Intervention: PCL-deficient knee
Number of subjects: 8

Group type: COMPARATOR
Intervention: Contralateral normal knee
Number of subjects: 8
Study: 1647192

Group type: EXPERIMENTAL
Intervention: NPC 567 (500 micrograms)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: NPC 567 coadministered with bradykinin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo coadministered with bradykinin
Number of subjects: 20
Study: 6336918

Group type: EXPERIMENTAL
Intervention: Intravenous cefoxitin in conjunction with standard bowel preparation
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard bowel preparation
Number of subjects: 241
Study: 30567626

Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil (EVOO)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Butter
Number of subjects: 11

Group type: COMPARATOR
Intervention: Low-fat (LF)
Number of subjects: 11
Study: 27727063

Group type: EXPERIMENTAL
Intervention: Accelerated-fractionation arm
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-fractionation arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: p16-positive oropharyngeal cancer (OPC) patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline QOL/PS scores
Number of subjects: 0
Study: 27015130

Group type: EXPERIMENTAL
Intervention: Mobi-C cervical total disc replacement
Number of subjects: 330

Group type: COMPARATOR
Intervention: ACDF (anterior cervical discectomy and fusion)
Number of subjects: 330
Study: 24310107

Group type: EXPERIMENTAL
Intervention: Cases with current ulcers
Number of subjects: 273

Group type: COMPARATOR
Intervention: Controls (ulcer naïve)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Loss of sensation
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: ABPI (ankle-brachial pressure index)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Forefoot deformity
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: HAQ score
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: History of foot surgery
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Plantar pressures and joint counts
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Suspected cutaneous vasculitis
Number of subjects: 273
Study: 22473785

Group type: EXPERIMENTAL
Intervention: Acute hypoxia
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normoxia (control)
Number of subjects: 9
Study: 19733660

Group type: EXPERIMENTAL
Intervention: gelatin capsules loaded with fast‐disintegrating starch pellets (group P)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: lyophilized lactose/skimmed milk (group L)
Number of subjects: 18

Group type: COMPARATOR
Intervention: no intervention (group C)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: all groups (P, L, C)
Number of subjects: 18
Study: 17513815

Group type: EXPERIMENTAL
Intervention: Telephone intervention (4 to 8 calls over 1 month)
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 305
Study: 12601075

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (target INR, 1.5 to 2.0)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin
Number of subjects: 508
Study: 10959813

Group type: EXPERIMENTAL
Intervention: Interferon combined with ribavirin (1000-1200 mg/day) for 24 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Interferon alone (5 million units, 3 times a week)
Number of subjects: 112
Study: 8899116

Group type: EXPERIMENTAL
Intervention: Salmeterol (10(-6)M)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Terbutaline (10(-5)M)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Salmeterol (10(-6)M) and Terbutaline (10(-5)M)
Number of subjects: 8
Study: 1654194

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) treatment with 370 mg of monoclonal antibody 494/32 (100 mg loading dose, 9 x 30 mg continuing within 10 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: No additional anti-cancer treatment (Control)
Number of subjects: 61
Study: 6352612

Group type: EXPERIMENTAL
Intervention: Ceftazidime alone
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Ceftazidime and tobramycin combination
Number of subjects: 275
Study: 30506594

Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation in Kangaroo position
Number of subjects: 66

Group type: COMPARATOR
Intervention: Incubator
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Kinesthetic stimulation in Kangaroo position initiated before five days of life
Number of subjects: 66
Study: 27649930

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 301
Study: 26089136

Group type: EXPERIMENTAL
Intervention: Controlled-Release Sarpogrelate 300 mg once daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate-Release Sarpogrelate 100 mg three times daily
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Controlled-Release Sarpogrelate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Immediate-Release Sarpogrelate
Number of subjects: 32
Study: 23387338

Group type: EXPERIMENTAL
Intervention: Fan-type rapid maxillary expansion (FRME)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rapid maxillary expansion (RME)
Number of subjects: 42
Study: 21629370

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Minimal acupuncture
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 78

Group type: COMPARATOR
Intervention: Actigraphy measures
Number of subjects: 78

Group type: COMPARATOR
Intervention: Depressive symptoms
Number of subjects: 78

Group type: COMPARATOR
Intervention: Daily functioning
Number of subjects: 78

Group type: COMPARATOR
Intervention: Hypnotic consumption
Number of subjects: 78
Study: 19083075

Group type: EXPERIMENTAL
Intervention: 25 microg of vitamin D3 daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 50 microg of vitamin D3 daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 75 microg of vitamin D3 daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 100 microg of vitamin D3 daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 200 microg of vitamin D3 daily
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: S-calcium (not specified dosage)
Number of subjects: 131
Study: 16784967

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before each meal (300 mg/d) for 3 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no acarbose)
Number of subjects: 20
Study: 16344404

Group type: EXPERIMENTAL
Intervention: ISDN/HYD therapy
Number of subjects: 0
Study: 10596659

Group type: EXPERIMENTAL
Intervention: 2,200 mg amoxicillin‐clavulanic acid
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 1,500 mg cefuroxime
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 8691923

Group type: EXPERIMENTAL
Intervention: r-hGH treatment (subcutaneous dose ranged between 12.2 and 21.0 U/m2 per week for the first 2 years, then 20 U/m2 per week thereafter)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Observation group (7 short children who declined treatment)
Number of subjects: 23
Study: 1679324

Group type: EXPERIMENTAL
Intervention: Rational Emotive Therapy (RET)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: exposure in vivo
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: exposure in vivo (after RET)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (waiting period)
Number of subjects: 21
Study: 7114076

Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients with autoimmune features
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Patients without autoimmune features
Number of subjects: 88
Study: 31157528

Group type: EXPERIMENTAL
Intervention: Positive bonding of other group members in the middle of the group
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Individual group member negative relationships in early and middle sessions
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Positive working early in the group
Number of subjects: 168
Study: 29044718

Group type: EXPERIMENTAL
Intervention: Child‐ and Family‐Focused Cognitive Behavioral Therapy (CFF‐CBT)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Psychotherapy treatment‐as‐usual (TAU)
Number of subjects: 71
Study: 26883141

Group type: EXPERIMENTAL
Intervention: TC-based CCRT (carboplatin AUC: 2, paclitaxel 35mg/m²) followed by TC-based consolidation chemotherapy (carboplatin AUC: 5, paclitaxel 175mg/m²)
Number of subjects: 31
Study: 25402544

Group type: EXPERIMENTAL
Intervention: Telaprevir (TVR) twice daily (bid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Telaprevir (TVR) every 8-h (q8h)
Number of subjects: 100
Study: 22538078

Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 20

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 20
Study: 19732888

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combined metformin and clomiphene citrate
Number of subjects: 0
Study: 18507956

Group type: EXPERIMENTAL
Intervention: Advanced dressings
Number of subjects: 200

Group type: COMPARATOR
Intervention: Traditional medications
Number of subjects: 200
Study: 16005564

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 975

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg and 10 mg
Number of subjects: 975
Study: 11840081

Group type: COMPARATOR
Intervention: Full dose Hib polysaccharide-tetanus toxoid conjugate vaccine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 1/10 dilution of Hib polysaccharide-tetanus toxoid conjugate vaccine
Number of subjects: 168
Study: 10354656

Group type: EXPERIMENTAL
Intervention: Lithium (1,200 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 8577796

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (70 mg)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (250 mg)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Caffeine deprivation (overnight)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Caffeine deprivation (at least 7 days)
Number of subjects: 67
Study: 1959958

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days
Number of subjects: 418

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 418

Group type: EXPERIMENTAL
Intervention: 60 mg elemental iron as ferrous sulphate combined with 500 micrograms folic acid, daily for 100 days (if started by 16-19 weeks of gestation)
Number of subjects: 418
Study: 31675919

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 IU of 25(OH)D in a single oral administration)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 29246284

Group type: EXPERIMENTAL
Intervention: ALA-DAG (2.5 g/day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: ALA-TAG (2.5 g/day)
Number of subjects: 17
Study: 26672246

Group type: EXPERIMENTAL
Intervention: Catheter group (stellate ganglion catheter retention with ropivacaine block 1 time/day)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Block group (stellate ganglion puncture and ropivacaine block 1 time/day)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group (routine comprehensive treatment only)
Number of subjects: 126
Study: 23301821

Group type: EXPERIMENTAL
Intervention: NBoNT (20 U)
Number of subjects: 314

Group type: COMPARATOR
Intervention: OBoNT (20 U)
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: NBoNT and OBoNT
Number of subjects: 314
Study: 21471262

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion starting after induction of anesthesia with an initial bolus of 12 μg·kg(‐1) for 10 min, followed by 0.1 μg·kg(‐1)·min(‐1) for 24 h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Intra-aortic balloon pump started 16‐18 h before surgery
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Levosimendan infusion
Number of subjects: 40
Study: 19398080

Group type: EXPERIMENTAL
Intervention: Electrical muscle stimulation (EMS) training for 8 weeks, 1 hour, 5 days a week
Number of subjects: 10
Study: 15121557

Group type: EXPERIMENTAL
Intervention: Single dose of 600 microg misoprostol
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Double dose of 600 microg misoprostol
Number of subjects: 169
Study: 11477729

Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365 (20, 40, 80, and 100 mg)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365 (80 mg and 100 mg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Aerosolized INS 365
Number of subjects: 84
Study: 9928921

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 43
Study: 8035394

Group type: EXPERIMENTAL
Intervention: Enteric coated naproxen (NAP‐EC)
Number of subjects: 355

Group type: COMPARATOR
Intervention: Standard immediate release naproxen (NAP‐STD)
Number of subjects: 355
Study: 3059882

Group type: EXPERIMENTAL
Intervention: Nebulized atropine methylnitrate (AMN)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31220920

Group type: EXPERIMENTAL
Intervention: Immediate workbook (ACT self-help bibliotherapy)
Number of subjects: 503

Group type: COMPARATOR
Intervention: Wait-list condition (control)
Number of subjects: 503
Study: 30969313

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 26797777

Group type: EXPERIMENTAL
Intervention: Radica plasma disinfection system
Number of subjects: 27

Group type: COMPARATOR
Intervention: Standard cleaning
Number of subjects: 27
Study: 25312436

Group type: EXPERIMENTAL
Intervention: Perindopril-indapamide (4/1.25 mg)
Number of subjects: 11140
Study: 23437857

Group type: EXPERIMENTAL
Intervention: Behavioral parent-only intervention program (12 group sessions over 4 months)
Number of subjects: 1
Study: 21041512

Group type: EXPERIMENTAL
Intervention: Customized orthoses using the D3D system
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no orthoses)
Number of subjects: 400
Study: 18841741

Group type: EXPERIMENTAL
Intervention: Ionic toothbrush
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional toothbrush
Number of subjects: 20
Study: 16320073

Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels during operation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels between adenocarcinoma and squamous carcinoma
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CK19 mRNA levels between PV-first group and PA-first group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CEA mRNA levels during operation
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CEA mRNA levels between PV-first group and PA-first group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation between preoperative T-stage and perioperative CEA mRNA
Number of subjects: 33

Group type: COMPARATOR
Intervention: Detection of circulating epithelial cells in benign lung disease patients
Number of subjects: 33
Study: 14516415

Group type: EXPERIMENTAL
Intervention: Ketorolac (10 mg, p.o.)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50